SCHEMBL794093

SCHEMBL794093

CC(C)NC(=O)c1nc2c(N3CCC4(CC3)C(=O)Nc3ccccc34)ncnc2n1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.42
PIK3R1 P27986 1/20 0.42
TNKS O95271 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
CNR1 P21554 2/20 0.38
CNR2 P34972 2/20 0.38
OPRM1 P35372 1/20 0.37
OPRK1 P41145 1/20 0.37
OPRL1 P41146 1/20 0.37
HTR1A P08908 8/20 0.37
HTR2A P28223 8/20 0.37
HTR7 P34969 8/20 0.37
HTR6 P50406 8/20 0.37
ROCK2 O75116 2/20 0.36
AKT1 P31749 2/20 0.36
AKT2 P31751 2/20 0.36
AKT3 Q9Y243 2/20 0.36
MAPK14 Q16539 1/20 0.36
IP6K1 Q92551 1/20 0.35
BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL787827 0.92 AKT1 (0.45) PIK3CDPIK3R1TNKSTNKS2HTR1A
SCHEMBL10230085 0.91 PIK3CD (0.43) PIK3CDPIK3R1TNKSTNKS2CNR1
SCHEMBL10229914 0.89 PIK3CD (0.41) PIK3CDPIK3R1TNKSTNKS2CNR1
SCHEMBL15485770 0.89 PIK3CD (0.46) PIK3CDPIK3R1TNKSTNKS2CNR1
SCHEMBL788844 0.89 TNKS (0.42) PIK3CDPIK3R1TNKSTNKS2CNR1
SCHEMBL15485390 0.88 PIK3CD (0.42) PIK3CDPIK3R1TNKSTNKS2CNR1
SCHEMBL794500 0.88 PIK3CD (0.48) PIK3CDPIK3R1TNKSTNKS2CNR1
SCHEMBL795082 0.88 PIK3CD (0.45) PIK3CDPIK3R1TNKSTNKS2CNR1
SCHEMBL787977 0.87 PIK3CD (0.46) PIK3CDPIK3R1TNKSTNKS2CNR1
SCHEMBL15485449 0.87 HTR1A (0.42) PIK3CDPIK3R1TNKSTNKS2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616469-B1 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE EXELIXIS INC (US) 2016-10-26 EP claimed
US-9346807-B2 Inhibitors of PI3K-delta and methods of their use and manufacture EXELIXIS, INC. (US) 2016-05-24 US claimed
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-02-27 US claimed
EP-2616469-B1 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE EXELIXIS INC (US) 2016-10-26 EP disclosed
EP-2616469-B1 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE EXELIXIS INC (US) 2016-10-26 EP disclosed
US-9346807-B2 Inhibitors of PI3K-delta and methods of their use and manufacture EXELIXIS, INC. (US) 2016-05-24 US disclosed
US-9346807-B2 Inhibitors of PI3K-delta and methods of their use and manufacture EXELIXIS, INC. (US) 2016-05-24 US disclosed
US-9346807-B2 Inhibitors of PI3K-delta and methods of their use and manufacture EXELIXIS, INC. (US) 2016-05-24 US disclosed
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-02-27 US disclosed
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-02-27 US disclosed
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140058103-A1 Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture PIK3CD, PIK3CA, PIK3R5 PIK3CD 1/4885PIK3R1 6/4885TNKS 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.